Top

Published in:

Open Access 01-09-2021 | Prostate Cancer | Original Article

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer

Authors: Yasuhide Miyoshi, Sohgo Tsutsumi, Masato Yasui, Takashi Kawahara, Ko-ichi Uemura, Naruhiko Hayashi, Masahiro Nozawa, Kazuhiro Yoshimura, Hiroji Uemura, Hirotsugu Uemura

Published in: World Journal of Urology | Issue 9/2021

Abstract

Purpose

We evaluated the predictive factors for completion of all six cycles of radium-223 (Ra-223) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). We also developed a novel prediction model for Ra-223 treatment completion using these predictors.

Methods

We retrospectively reviewed data from 122 patients with mCRPC who were treated with Ra-223. The predictive factors for the completion of six cycles of Ra-223 treatment were evaluated. Statistically significant predictive factors were then used to develop a prediction model for treatment completion. Finally, using this prediction model, we classified the overall survival (OS) of the entire cohort into three groups.

Results

We identified three significant variables as the predictive factors for treatment completion: baseline alkaline phosphatase (ALP) level, baseline hemoglobin (Hb) level, and baseline pain. The three groups generated using the prediction model were: group 1 (patients with three predictive factors, i.e., ALP < median, Hb ≥ median, and no pain), group 2 (patients with one to two predictive factors), and group 3 (patients without any predictive factors). The treatment completion rates differed between the three groups significantly. Furthermore, the OS also differed among the groups significantly.

Conclusion

Our study suggested that the baseline ALP level, baseline Hb level, and baseline pain were the predictive factors of completion of all six cycles of Ra-223 treatment in patients with mCRPC. Our prediction model consisting of these factors could predict not only the completion of Ra-223 treatment, but also the post-treatment survival. This model can thus be useful for selection of patients for Ra-223 treatment.

Available only for authorised users

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. https://doi.org/10.1056/NEJMoa1213755CrossRefPubMed

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland OS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15(7):738–746. https://doi.org/10.1016/s1470-2045(14)70183-4CrossRefPubMed

Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 27(5):868–874. https://doi.org/10.1093/annonc/mdw065CrossRefPubMedPubMedCentral

Takahashi S, Kakehi Y, Masumori N, Hosono M, Kinuya S, Okayama Y, Sunaya T, Okumura M, Uemura H (2020) Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: a Japanese post-marketing study (PMS). J Clin Oncol 38(6):236CrossRef

Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O (2020) Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-0236-0CrossRefPubMedPubMedCentral

Hashimoto K, Miyoshi Y, Shindo T, Hori M, Tsuboi Y, Kobayashi K, Fukuta F, Tanaka T, Miyamoto S, Maehana T, Okada M, Nishiyama N, Yanase M, Kato R, Hotta H, Kunishima Y, Takahashi A, Hinotsu S, Sakata KI, Kitamura H, Uemura H, Masumori N (2020) Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. Cancer Med. https://doi.org/10.1002/cam4.3459CrossRefPubMedPubMedCentral

Saad F, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Nilsson S, Miller K, Wirth M, Reeves J, Seger M, Carles J, Heidenreich A (2019) Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program. Clin Genitourin Cancer 17(5):348.e345-355.e345. https://doi.org/10.1016/j.clgc.2019.05.012CrossRef

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Levy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM, Radium-223 International Early Access Program I (2016) Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 17(9):1306–1316. https://doi.org/10.1016/s1470-2045(16)30173-5CrossRefPubMed

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):408–419. https://doi.org/10.1016/s1470-2045(18)30860-xCrossRefPubMed

10.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159. https://doi.org/10.1200/jco.2007.12.4487CrossRefPubMed

11.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

12.

Parimi S, Tsang E, Alexander A, McKenzie M, Bachand F, Sunderland K, Chi KN, Aparicio M, Worsley D, Tyldesley S (2017) A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. Can Urol Assoc J 11(10):350–355. https://doi.org/10.5489/cuaj.4415CrossRefPubMedPubMedCentral

13.

Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, Liu Q, Haber MT, Leutzinger EE, Al-Hakim A, Chen W, Palmby T, Alebachew E, Sridhara R, Ibrahim A, Justice R, Pazdur R (2014) Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 20(1):9–14. https://doi.org/10.1158/1078-0432.Ccr-13-2665CrossRefPubMed

14.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M (2018) EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 45(5):824–845. https://doi.org/10.1007/s00259-017-3900-4CrossRefPubMed

Title: A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
Authors: Yasuhide Miyoshi
Sohgo Tsutsumi
Masato Yasui
Takashi Kawahara
Ko-ichi Uemura
Naruhiko Hayashi
Masahiro Nozawa
Kazuhiro Yoshimura
Hiroji Uemura
Hirotsugu Uemura
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: World Journal of Urology / Issue 9/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-021-03639-z

At a glance: The STEP trials

Springer Medicine

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2021

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma

Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?

Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy

A prospective evaluation of high- and low-power holmium laser settings for transurethral lithotripsy in the management of adults with large bladder calculi

Incidence and risk factors of venous thromboembolism after percutaneous nephrolithotomy: a single-center experience

Retropulsion force in laser lithotripsy—an in vitro study comparing a Holmium device to a novel pulsed solid-state Thulium laser